HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

rontalizumab

targets interferon-alpha

Also Known As:

rhumab ifnalpha; rhumab-ifnalpha

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kennedy, William P: 2 articles (01/2016 - 11/2012)
2.	Maciuca, Romeo: 2 articles (01/2016 - 11/2012)
3.	McBride, Jacqueline M: 2 articles (01/2016 - 11/2012)
4.	Davis, John C: 1 article (01/2016)
5.	Kalunian, Kenneth C: 1 article (01/2016)
6.	Merrill, Joan T: 1 article (01/2016)
7.	Townsend, Michael J: 1 article (01/2016)
8.	Wei, Xiaohui: 1 article (01/2016)
9.	Abbas, Alexander R: 1 article (11/2012)
10.	Drappa, Jorn: 1 article (11/2012)

Related Diseases

1.

Systemic Lupus Erythematosus (Libman-Sacks Disease)

11/01/2012 - "Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study."
01/01/2016 - "A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)."
01/01/2016 - "To examine the safety and efficacy of rontalizumab, a humanised IgG1 anti-interferon α (anti-IFN-α) monoclonal antibody, in patients with moderate-to-severe systemic lupus erythematosus (SLE). "

Related Drugs and Biologics

1.	Interferons
2.	Immunoglobulin G (IgG)
3.	Monoclonal Antibodies